

Iñigo Lozano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2790315/publications.pdf>

Version: 2024-02-01

67
papers

161
citations

1307594

7
h-index

1199594

12
g-index

68
all docs

68
docs citations

68
times ranked

253
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19 pandemic, mechanical reperfusion and 30-day mortality in ST elevation myocardial infarction. <i>Heart</i> , 2022, 108, 458-466.	2.9	28
2	The dilemma of surgical or percutaneous approach in aortic stenosis: A reliable risk score is needed. <i>American Heart Journal</i> , 2010, 160, e1.	2.7	21
3	Diffuse Coronary Artery Disease Not Amenable to Revascularization: Long-term Prognosis. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2015, 68, 631-633.	0.6	17
4	Enfermedad difusa no revascularizable de los tres vasos coronarios: pronóstico a largo plazo. <i>Revista Espanola De Cardiologia</i> , 2015, 68, 631-633.	1.2	9
5	Aterectomía de rotación por vía radial con catéter guía 7,5 Fr sin introductor. <i>Revista Espanola De Cardiologia</i> , 2011, 64, 247-248.	1.2	8
6	Immediate and Long-Term Results of Drug-Eluting Stents in Mammary Artery Grafts. <i>American Journal of Cardiology</i> , 2015, 116, 1695-1699.	1.6	8
7	Limitaciones al uso de los nuevos antiagregantes en los síndromes coronarios agudos relacionadas con las características de los pacientes. <i>Revista Espanola De Cardiologia</i> , 2015, 68, 448-450.	1.2	6
8	Long-term antiplatelet therapy with the polypill after stenting: More information is necessary. <i>International Journal of Cardiology</i> , 2016, 207, 87-88.	1.7	6
9	Acute Coronary Syndromes, Gastrointestinal Protection, and Recommendations Regarding Concomitant Administration of Proton-Pump Inhibitors (Omeprazol/Esomeprazole) and Clopidogrel. <i>American Journal of Cardiology</i> , 2016, 117, 366-368.	1.6	5
10	Use of the New Antiplatelet Agents in Acute Coronary Syndromes: Limitations Related to Patient Characteristics. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2015, 68, 448-450.	0.6	3
11	SYNTAX score and left main stenting: Do we need clinical variables to predict outcomes?. <i>American Heart Journal</i> , 2010, 159, e25.	2.7	2
12	Severe coronary disease not amenable to revascularization: Are the series clearly defined?. <i>Catheterization and Cardiovascular Interventions</i> , 2014, 84, E1.	1.7	2
13	Care Network for ST-elevation Myocardial Infarction: What Is the Ideal Catchment Area for Primary Angioplasty?. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2015, 68, 444-445.	0.6	2
14	Factors Contributing to the Low Rate of Surgical Revascularization in Spain. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2015, 68, 911.	0.6	2
15	Factores que contribuyen a la reducida indicación de revascularización quirúrgica en España. <i>Revista Espanola De Cardiologia</i> , 2015, 68, 911.	1.2	2
16	Demanda futura de procedimientos intervencionistas en cardiopatía estructural. ¿Es sensato realizar TAVI solo en centros con cirugía cardíaca?. <i>Revista Espanola De Cardiologia</i> , 2017, 70, 307.	1.2	2
17	Future Demand for Interventional Procedures in Structural Heart Disease. Is It Wise to Perform TAVI Only in Centers With On-site Cardiac Surgery?. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2017, 70, 307.	0.6	2
18	Rotational Atherectomy Through Radial Access With a 7.5 Fr Sheathless Guiding Catheter. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2011, 64, 247-248.	0.6	1

#	ARTICLE	IF	CITATIONS
19	Sostenibilidad del sistema sanitario: más allá de los análisis de coste-efectividad. Revista Espanola De Cardiologia, 2016, 69, 880-881.	1.2	1
20	Sustainability of the Health System: Beyond Cost-effectiveness Analyses. Revista Espanola De Cardiologia (English Ed), 2016, 69, 880-881.	0.6	1
21	Outpatient percutaneous coronary intervention: An old technique necessary in the present and future. International Journal of Cardiology, 2016, 223, 224-225.	1.7	1
22	Chronic Kidney Disease and Antiplatelet Therapy. JACC: Cardiovascular Interventions, 2018, 11, 319-320.	2.9	1
23	Coronary Sinus Reducer Implantation. JACC: Cardiovascular Interventions, 2018, 11, 1658.	2.9	1
24	Definition of Myocardial Infarction Type 4a: Can We Define Its Diagnosis and Systematize Clinical Practice?. Revista Espanola De Cardiologia (English Ed), 2019, 72, 695-696.	0.6	1
25	Antiplatelet Therapy After Stenting at the Crossroads. JACC: Cardiovascular Interventions, 2021, 14, 929-930.	2.9	1
26	Percutaneous intervention in patients with cancer: can we offer an improvement in safety?. European Heart Journal, 2021, , .	2.2	1
27	Definición de infarto tipo 4a: ¿podemos definir mejor su diagnóstico y sistematizar la práctica clínica?. Revista Espanola De Cardiologia, 2019, 72, 695-696.	1.2	1
28	Myocardial infarction in saphenous percutaneous intervention: Are we really doing our best?. American Heart Journal, 2009, 158, e39.	2.7	0
29	Reperfusion in Acute Myocardial Infarction. JACC: Cardiovascular Interventions, 2010, 3, 1093.	2.9	0
30	Elevation of high-sensitivity cardiac troponin T and composite end points in randomized trials. American Heart Journal, 2010, 160, e47.	2.7	0
31	Percutaneous Coronary Intervention Through an Axillo-Bifemoral Bypass. Revista Espanola De Cardiologia (English Ed), 2011, 64, 1073-1074.	0.6	0
32	Which Should Be the Control Arm in Trials of Antiplatelet Therapies?. American Journal of Cardiology, 2015, 116, 493-494.	1.6	0
33	Lights and Shadows of Antiplatelet Therapy in Primary Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2015, 8, 1001-1002.	2.9	0
34	Has Prasugrel Been Compared Correctly With Clopidogrel in Non-ST-Segment Elevation Acute Coronary Syndrome?. Journal of the American College of Cardiology, 2015, 65, 1716-1717.	2.8	0
35	Radial Artery in Breast Cancer Survivors. JACC: Cardiovascular Interventions, 2015, 8, 1275-1276.	2.9	0
36	The Role of Drug-Eluting Balloons in Bifurcations. JACC: Cardiovascular Interventions, 2015, 8, 1273-1274.	2.9	0

#	ARTICLE	IF	CITATIONS
37	Usefulness of Rotational Atherectomy in the Current Era. American Journal of Cardiology, 2016, 117, 1858-1859.	1.6	0
38	Escalating Loading Dose Regimens of Ticagrelor in Primary Percutaneous Intervention. JACC: Cardiovascular Interventions, 2016, 9, 623-624.	2.9	0
39	The dilemma of identification of the culprit lesion in multivessel disease in patients with complex collateral circulation. International Journal of Cardiology, 2016, 223, 34-36.	1.7	0
40	Usefulness of the catheter extension in combination with the fractional flow reserve in coronary grafts. International Journal of Cardiology, 2016, 222, 287-288.	1.7	0
41	Consensus Document on Polypill and Secondary Prevention. Does It Include Patients With Stents?. Revista Espanola De Cardiologia (English Ed), 2016, 69, 995.	0.6	0
42	Documento de consenso del policomprimido en prevención secundaria. ¿Incluye a los pacientes con stent?. Revista Espanola De Cardiologia, 2016, 69, 995.	1.2	0
43	Pre-Hospital Ticagrelor in ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Interventions, 2016, 9, 1414-1415.	2.9	0
44	Toma de decisiones por el equipo cardiaco en España: ¿hay margen de mejora?. Revista Espanola De Cardiologia, 2016, 69, 533-534.	1.2	0
45	Heart Team Decision-making in Spain: Is There Room for Improvement?. Revista Espanola De Cardiologia (English Ed), 2016, 69, 533-534.	0.6	0
46	Thrombectomy in Primary Angioplasty: Do the Latest Large Studies Address the Doubts About Its Usefulness?. Revista Espanola De Cardiologia (English Ed), 2016, 69, 230-231.	0.6	0
47	Trombectomía en angioplastia primaria: ¿aclaran los últimos grandes estudios las dudas sobre su utilidad?. Revista Espanola De Cardiologia, 2016, 69, 230-231.	1.2	0
48	Microvascular Function in Ischemic Heart Disease. JACC: Cardiovascular Interventions, 2016, 9, 392-393.	2.9	0
49	Cardiovascular Disease and Individual Income: A Factor Not to Be Overlooked. Revista Espanola De Cardiologia (English Ed), 2017, 70, 222.	0.6	0
50	Enfermedad cardiovascular y renta individual: un factor que debe tener en cuenta. Revista Espanola De Cardiologia, 2017, 70, 222.	1.2	0
51	Iniciativas para conseguir una atención excelente en el síndrome coronario agudo. Revista Espanola De Cardiologia, 2017, 70, 1026-1027.	1.2	0
52	Initiatives to Achieve Excellence in the Care of Acute Coronary Syndrome. Revista Espanola De Cardiologia (English Ed), 2017, 70, 1026-1027.	0.6	0
53	Cangrelor or Abciximab as First Choice in Cardiogenic Shock. JACC: Cardiovascular Interventions, 2017, 10, 2467-2468.	2.9	0
54	Antithrombotic Therapy After Percutaneous Aortic Valve Implantation: Large Gaps for a Matter of Extreme Importance. Revista Espanola De Cardiologia (English Ed), 2018, 71, 308.	0.6	0

#	ARTICLE	IF	CITATIONS
55	De-Escalation of the P2Y12 Inhibitor After Acute Coronary Syndromes According to On-Treatment Platelet Reactivity. JACC: Cardiovascular Interventions, 2018, 11, 507-508.	2.9	0
56	Tratamiento antitrombótico tras implante percutáneo de válvula aórtica: grandes lagunas para una cuestión de extrema importancia. Revista Espanola De Cardiologia, 2018, 71, 308.	1.2	0
57	Implementation of Institutional Protocols for Patients With Acute Coronary Syndrome: Nonclinical Factors Also Matter. American Journal of Cardiology, 2018, 122, 1804-1805.	1.6	0
58	Cost of Therapies in Acute Coronary Syndromes. Journal of the American College of Cardiology, 2018, 71, 2710.	2.8	0
59	Assessment of Platelet Reactivity After Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2019, 12, 801-802.	2.9	0
60	Duration of Dual-Antiplatelet Therapy After Left Main Stenting. JACC: Cardiovascular Interventions, 2019, 12, 690.	2.9	0
61	Same-Day Discharge After Elective Percutaneous Intervention. JACC: Cardiovascular Interventions, 2019, 12, 2324.	2.9	0
62	Incidence and Outcomes of Surgical Bailout During TAVR. JACC: Cardiovascular Interventions, 2019, 12, 2439.	2.9	0
63	Therapeutic Window of P2Y12 Inhibition. JACC: Cardiovascular Interventions, 2019, 12, 2434.	2.9	0
64	Strut Thickness and Patient's Outcomes in Different End Points After Stent Implantation. American Journal of Cardiology, 2019, 123, 863-864.	1.6	0
65	Percutaneous Intervention in Bifurcations After the DKCRUSH-V Trial. JACC: Cardiovascular Interventions, 2020, 13, 141-142.	2.9	0
66	Scientific evidence and expert opinion. Why is TAVI different?. Revista Espanola De Cardiologia (English) Tj ETQq0 0,0rgBT /Oyerlock 10	0.6	0
67	Cobalt-chromium stents in long lesions of large vessels: clinical and angiographic results. Texas Heart Institute Journal, 2011, 38, 35-41.	0.3	0